Also 2019 being a successful year
Eleven of the twelve subsidiaries contribute to the positive development of Geistlich Pharma. The overall result is a mid single-digit growth rate. The growth impulse is particularly strong in the Asia-Pacific region.
Solid development of all three business units
All product groups in the market for biomaterials can grow, with the Chinese and Indian markets developing particularly well. Sales and revenue figures in the Surgery business unit are also pointing upward, with two major markets, Germany and Brazil, performing solidly. The third business unit, Medical, clearly exceeded expectations, with South Korea as a major sales driver. Just launched in the summer of 2019, the Geistlich Derma-Gide® product in wound healing rounds off the positive result. The two smaller business units Surgery and Medical are increasingly asserting themselves in their markets with regeneration solutions and with the core values anchored at Geistlich Pharma. An important success factor for the 2019 result is the global orientation of the Biomaterials business unit, with the two business units Surgery and Medical following with increasingly international activities. Finally, the increased, focused support of distributors and dental chains is proving successful.